Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis

发布时间：2023-11-14 / 浏览次数：135 次

上一篇： In vivo pharmacodynamic study of contezolid acefosamil, a prodrug of contezolid for oral and intravenous administration

下一篇： Preclinical toxicity evaluation of novel antibacterial contezolid acefosamil in rats and dogs

返回列表